|
Humedix is a biotechnology company that develops and manufactures healthcare products based on biocompatible hyaluronic acid and PDRN technologies. The company operates through two main segments: an aesthetic division and a contract manufacturing organization (CMO) division. Its aesthetic portfolio includes hyaluronic acid fillers such as Elravie Premier and Revoline, botulinum toxin products like Rize Tox, dermal cosmetics under the Elravie brand, and medical devices including DermaShine and DermaAcne. In the CMO segment, Humedix produces specialized pharmaceuticals, arthritis treatments such as Hihyalonce, High Hyal Plus, and High Hyal, ophthalmic solutions like Prosan eye drops, and active pharmaceutical ingredients including hyaluronic acid, PDRN, and heparin sodium. The company supplies domestic and global healthcare markets, with products exported to regions including China, Europe, Southeast Asia, South America, and the Middle East. Humedix has established partnerships for joint research and development with companies such as HLB Pharma, Genen Bio, G2G Bio, Exostemtech, and Epibiotec, focusing on areas like obesity treatment, bio-dressing, and long-acting injectables. Summarised from the company's own disclosures, fiscal year ended Mar 2026 |
Industry Biotechnology | Homepage humedix.com |
| Sector Healthcare | IR page — | |
|
Tags
hyaluronic acid, dermal fillers, botulinum toxin, arthritis treatment, ophthalmic solutions, active pharmaceutical ingredients, dermocosmetics, contract manufacturing, pdrn, biocompatible polymers, Elravie Premier, Revoline, Rize Tox, Elravie Cosmetic, DermaShine, DermaAcne, Humedex Dexamethasone Phosphate Sodium Injection, Humedex Lincomycin Hydrochloride Injection, Revitalex Injection, Hudaxin Injection, Eripotin Prefilled Injection, Hihyalonce Injection, High Hyal Plus Injection, High Hyal Injection, Prosan Eye Drops, Prosan 0.3% Eye Drops, High Eye Injection, Heparin Sodium, Elravie Deep Line, Elravie Deep Line-L, Revoline Hara-L, Elravie Premier Soft, Valpian, Humiya Injection, Kirielle, Derma Atom, Elravie Rituo, Red Booster, Olipit Injection
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | ₩ 390.802B |
| Market cap (USD) | $ 287.623M |
| P/E | 8.01 |
| PEG | 0.23 |
| P/BV | 1.27 |
| P/S | 2.20 |
| P/OCF | 10.04 |
| P/FCF | 15.11 |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 19.6% |
| ROI | 17.3% |
| ROIC | 11.5% |
| Profit margin | 30.5% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | Yes |
| Revenue up 3y | Yes |
| Revenue up 5y | Yes |
| Earnings growth 3y (net profit CAGR) | 34.8% |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | No |
| Buying back stock | No |
| Diluting (TTM) | No |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | — |
| Quality score | 52.9% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 170.053B | 161.873B | 152.274B | 123.173B | 110.992B | 98.481B | 78.619B | 64.832B | 54.727B | 47.134B | 42.133B | 29.182B | 23.544B |
| Net profit | 51.786B | 39.259B | 24.821B | 21.154B | 10.051B | 15.084B | 10.42B | 9.208B | 11.548B | 10.275B | 11.623B | 6.642B | 9.137B |
| Free cash flow | 37.21B | 42.146B | 21.882B | 30.872B | 5.441B | 6.07B | 4.477B | 10.821B | -10.634B | -14.753B | 1.034B | 6.055B | 4.362B |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||||
| Trade receivables (KRW) | 16.7B | 17.6B | 14.3B | 24B | 20.7B | 22.2B | 21.2B | 19.7B | 20.5B | 29.3B |
| ↳ YoY growth | +50.6% | +5.3% | -18.6% | +67.0% | -13.7% | +7.2% | -4.3% | -7.3% | +4.1% | +42.9% |
| ↳ 5y CAGR | +25.3% | +26.7% | +13.2% | +5.8% | +3.8% | +6.5% | -3.1% | +7.2% | ||
| Other receivables (KRW) | — | — | — | — | — | — | — | 925M | 2.42B | 2.66B |
| Borrowings, current (KRW) | 1.38B | — | — | — | — | — | — | — | — | — |
| Borrowings, non-current (KRW) | 9.22B | — | — | — | — | — | — | — | — | — |
| Lease liabilities (KRW) | — | — | — | — | — | — | — | 2.7B | 2.96B | 1.36B |
| Cash and deposits (KRW) | 59.8B | 38B | 29.9B | 19.1B | 28.7B | 9.35B | 90.7B | 80.2B | 110B | 39.9B |
| Intangible assets (KRW) | 855M | 881M | 862M | 4.16B | 6.95B | 3.18B | 3.05B | 2.58B | 2.37B | 2.35B |
| Right-of-use assets (KRW) | — | — | — | — | — | — | — | 2.65B | 2.86B | 1.3B |
| Net debt (borrowings + leases - cash) (KRW) | -49.2B | — | — | — | — | — | — | — | — | — |
| Cash flow detail | ||||||||||
| Operating cash flow (KRW) | 7.61B | 8.77B | 23.8B | 13.8B | 23.8B | 19.2B | 38.1B | 30.9B | 50.7B | 45.1B |
| Purchases of property, plant and equipment (KRW) | -22.4B | -19.4B | -13B | -9.33B | -17.7B | -13.7B | -7.23B | -9B | -8.6B | -7.94B |
| Purchases of intangible assets (KRW) | -36.8M | -97.9M | -177M | -8.38M | 0.00 | -1B | 0.00 | -26.6M | -66.8M | -76M |
| Dividends paid (cash effect) (KRW) | -2.6B | -4.29B | -5.16B | -5.34B | -4.76B | -3.76B | -3.76B | -7.08B | -5.95B | -10.8B |
| Share buybacks (cash effect) (KRW) | -2.98B | -4.88B | -5.15B | -151M | -2.99B | -7M | -5.98B | 0.00 | -3B | -5B |
| Interest paid (cash effect) (KRW) | -47.1M | — | — | — | — | — | — | -350M | — | -59.5M |
| Income taxes paid (cash effect) (KRW) | -3.67B | -2.97B | -1.7B | -1.22B | -2.17B | -1.02B | -2.36B | -12.7B | -5.07B | -9.43B |
| Free cash flow (OCF - PPE - intangibles) (KRW) | -14.8B | -10.7B | 10.6B | 4.47B | 6.07B | 4.44B | 30.9B | 21.9B | 42.1B | 37.1B |
| Income detail | ||||||||||
| Total comprehensive income (KRW) | 10.8B | 14B | 10.8B | 12.1B | 17.2B | 10.1B | 21.2B | 24.8B | 39.3B | 51.8B |
| Comprehensive income to owners (KRW) | 10.6B | 12.1B | 9.21B | 10.4B | 15.1B | — | — | — | — | — |
| Reported | Mar 30, 2018 | Mar 30, 2018 | Apr 1, 2019 | Mar 27, 2020 | Mar 11, 2021 | Mar 20, 2024 | Mar 20, 2024 | Mar 20, 2026 | Mar 20, 2026 | Mar 20, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpDisclosures filed with DART (material events and exchange disclosures), newest first, headlines as filed in Korean. The link opens the filing on DART.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding Humedix
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| AVEE | 0.01% | 445 | $ 7,357.55 | Nov 16, 2026 |
| DFSE | 0.01% | 1,780 | $ 30.036K | Nov 12, 2026 |
| DFEV | 0.00% | 3,028 | $ 51.094K | Nov 12, 2026 |
| DFEM | 0.00% | 9,239 | $ 155.899K | Nov 12, 2026 |
| DFAE | 0.00% | 6,157 | $ 103.893K | Nov 12, 2026 |
| DFAX | 0.00% | 4,989 | $ 84.184K | Nov 12, 2026 |
| AVEM | 0.00% | 14,503 | $ 239.79K | Nov 16, 2026 |
| AVSE | 0.00% | 72 | $ 1,190.43 | Nov 16, 2026 |
| AVXC | 0.00% | 437 | $ 7,225.28 | Nov 16, 2026 |